Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
- HIV / AIDs
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26749
IPSCIO Record ID: 29247
IPSCIO Record ID: 367305
Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.
The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
Dual adenoviral delivery of transgenes.
The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.
IPSCIO Record ID: 352695
– Allele-specific RNA Interference;
– In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
– RNA Interference for the Treatment of Gain-of-Function Disorders;
– Novel AAVs and Uses Thereof;
– CNS Targeting AAV Vectors and Methods of Use Thereof;
– Methods and Compositions for Controlling Efficacy of RNA Silencing;
– Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
– Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
from the Field.
The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.
The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.
IPSCIO Record ID: 294014
Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.
Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.
IPSCIO Record ID: 256218
Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al
Eshhar-NIH patent US 8,211,422, Eshhar et al
Eshhar-NIH pending application [US 13/281,560, Eshhar et al
KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.
IPSCIO Record ID: 372471
Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.
Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement. Target Antigens will be limited to the oncology associated antigens designated.
T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.
Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.
CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patientâ€™s genetically modified cells are intended to bind to and kill the target cancer cells.
The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.
The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.
IPSCIO Record ID: 1617
IPSCIO Record ID: 356951
The University grants, to the extent of the Licensed Territory, an exclusive license under the Patent Rights to make, have made, use, offer for sale, sell and import Licensed Products in the Licensed Field, with the right to sublicense.
Licensee focuses on providing novel oncology and hematology therapeutics.
IPSCIO Record ID: 41918
Adeno-Associated Virus (AAV) is a non-enveloped, single stranded DNA virus that can infect both nondividing and dividing cells. AAV is thought to be non-pathogenic to humans and only replicates in the presence of a helper virus. These features have made AAV a useful tool for gene delivery to a wide variety of cell types and an attractive vector for gene therapy.